1. Successful treatment for serious depression with suicidal risk in a heart transplant patient.
- Author
-
Arango-Posada MDM, Prada-Escobar AI, Marín-Hernández C, Monsalve-Franco V, and Restrepo-Bernal D
- Subjects
- Humans, Male, Middle Aged, Treatment Outcome, Severity of Illness Index, Heart Transplantation, Ketamine administration & dosage, Depressive Disorder, Major, Suicidal Ideation, Mirtazapine administration & dosage, Heart Failure
- Abstract
Introduction: Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes., Case Report: We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a score of 20/27 on the PHQ-9 depression screening scale. After receiving mirtazapine 30 mg/night for a week and persisting with a high suicide risk, it was decided to administer ketamine infusion for 24 h, with which a significant improvement in mood was observed, and the disappearance of suicidal ideation 24 h after the infusion., Discussion: Depression in transplant patients is a factor associated with graft loss and post-transplant mortality, in addition to favouring other negative outcomes such as deep vein thrombosis., Conclusions: Ketamine infusion was shown to be an effective and safe option to treat major depression with suicidal risk in a heart transplant patient., (Copyright © 2022 Asociación Colombiana de Psiquiatría. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF